联环药业股票讨论区

The company's earnings power may be weaker than reported due to unusual items. Without these items and business growth, next year's profit could be weaker.

Jiangsu Lianhuan Pharmaceutical's low P/E ratio may reflect investor expectations of underperformance compared to the broader market. The company's recent medium-term earnings trajectory is less attractive, leading investors to pay less for the stock, expecting limited growth rates to continue.